Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Dr Pan on the Novel Therapy Anito-Cel in Relapsed/Refractory Myeloma

July 10th 2025

Darren Pan, MD, highlights the novelty of anito-cel in relapsed/refractory multiple myeloma, including the difference in safety profile vs cilta-cel.

Dr Chari on the Evolving Determination of Transplant Eligibility in Multiple Myeloma

July 9th 2025

Ajai Chari, MD, expands on the evolving debate surrounding transplant eligibility determination in newly diagnosed multiple myeloma.

Long-Term Remission, OS With Cilta-Cel Sets New Benchmark for Survival Outcomes in R/R Myeloma

July 9th 2025

Peter Voorhees, MD, highlights 5-year follow-up data from the CARTITUDE-1 trial evaluating cilta-cel in relapsed/refractory multiple myeloma.

Dr Voorhees on the Clinical Implications of Cilta-Cel in Relapsed/Refractory Myeloma

July 9th 2025

Peter Voorhees, MD, details the clinical implications of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma

July 8th 2025

The EHA-EMN guidelines now include melphalan flufenamide for certain patients with relapsed/refractory multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

FDA Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma

July 2nd 2025

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for use in patients with relapsed/refractory multiple myeloma.

CHMP Provides Positive Opinion for MRD Negativity as an End Point for Regulatory Myeloma Clinical Trials

July 2nd 2025

The EMA’s CHMP has issued a positive opinion for the use of MRD-negative CR as an end point for regulatory clinical trials for patients with myeloma.

Clinical "Gray Areas" Persist Amid Evolving Multiple Myeloma Treatment Strategies

July 2nd 2025

Ajai Chari, MD, expanded on areas of uncertainty in multiple myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Approaches to Risk Stratification, Timing of Treatment Initiation Pose Challenges in Smoldering Myeloma

June 30th 2025

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

FDA Removes REMS Programs for All Currently Approved CD19- and BCMA-Directed CAR T-Cell Therapies in Hematologic Malignancies

June 30th 2025

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

FDA Approves Changes to Monitoring Requirements, Removal of REMS Programs for Liso-Cel and Ide-Cel in B-Cell Malignancies

June 27th 2025

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

JNJ-5322 Demonstrates Preliminary Efficacy and Is Safe in R/R Multiple Myeloma

June 26th 2025

The trispecific antibody JNJ-5322 showed preliminary efficacy and safety signals in BCMA- and GPRC5D-naive relapsed/refractory myeloma.

CHMP Recommends Isatuximab Plus VRd for Transplant-Eligible, Newly Diagnosed Myeloma

June 23rd 2025

CHMP issues positive opinion for isatuximab plus VRd in transplant-eligible, newly diagnosed multiple myeloma.

Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma

June 23rd 2025

Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Dr van de Donk on Initial Safety and Efficacy Findings From the First-In-Human Study of JNJ-5322 in R/R Multiple Myeloma

June 20th 2025

Niels van de Donk, MD, discusses initial safety and efficacy findings from the first-in-human study of JNJ-5322 in relapsed or refractory multiple myeloma.